Kupando is getting an additional €10 million (US$11.5 million) Series A financing to target tumors in oncology, and infectious diseases.

Altogether, this latest round brings the company’s total Series A funding to €23 million (US$26.47 million).

A Mission in Oncology and Infectious Diseases

Kupando is a biopharmaceutical company developing a toll-like receptor (TLR) 4/7 agonist stimulating innate immunity and inducing trained immunity. A Phase Ib clinical study of Kupando’s lead candidate, KUP101, targets advanced solid tumors.

In addition to oncology, Kupando is also focused on addressing infectious diseases, such as antimicrobial-resistant infections.

The company was founded, in part, due to CEO Johanna Halldack, MD,’s observation of natural animal resilience using innate immunity. Kupando says this system has been “historically undervalued yet critical.”

“Our mission is to leverage the natural resilience of the innate immune system to deliver truly transformative therapies,” Halldack said. “This additional funding … [is] instrumental in advancing KUP101 into clinical studies for solid tumors and accelerating our crucial work.”

Carma Fund has joined as a new investor with this financing round. Remiges Ventures led the funding, co-led by LifeCare Partners.

Previously existing investors made additional investments, as well. Among these were Brandenburg Kapital, High-Tech Gründerfonds and Ventura Biomed Investors.

Kupando Investors React

Carma Fund Managing Partner Martin Raditsch, PhD, said investors have confidence in Kupando’s science, team, and potential.

“Kupando’s unique approach to leveraging innate immunity holds immense promise across oncology and infectious diseases,” Raditsch said.

Echoing that: Kupando Advisory Board member and Remiges Ventures partner Kazuhiko Nonomura, PhD.

“We believe Kupando’s dual TLR 4/7 agonist technology, particularly KUP101, has the potential to redefine treatment paradigms,” Nonomura said. “We are excited to see the company transition to the clinical stage and unlock the full potential of its pipeline.”